Bojko Adriana, Ostasz Roksana, Białecka Monika, Klimowicz Adam, Malinowski Damian, Budawski Robert, Bojko Piotr, Droździk Marek, Kurzawski Mateusz
Department of Experimental and Clinical Pharmacology, Pomeranian Medical University, Szczecin, Poland.
Aesthetic Dermatology Center "Hippocrates", Szczecin, Poland.
Hum Immunol. 2018 Apr;79(4):213-217. doi: 10.1016/j.humimm.2018.02.003. Epub 2018 Feb 15.
The role of interleukin-23 is crucial in the pathogenesis of psoriasis, and IL23A, IL12B and IL23R genetic variants have been associated with the disease in genome-wide association studies. In the current paper we have conducted a confirmation study of the abovementioned genetic factors in a case-control analysis of 507 psoriatic patients and 396 controls from a Polish population, and subsequently analyzed the impact of genetic variants on response to topical and NB-UVB therapy in a subset of 306 patients. Case-control analysis revealed an association of IL12B rs3212227 and IL23R rs11209026 minor allele carrier status with reduced odds for psoriasis (OR = 0.66, 95%CI: 0.50-0.87, and OR = 0.41, 95%CI: 0.26-0.67, respectively), while HLA-C06 allele carriers were more frequent in patients group (OR = 4.56, 95%CI: 3.41-6.10). The studied polymorphic variants of IL12B, IL23A, and IL23R genes did not influence therapy outcome, i.e. there were no significant differences in PASI reduction between patients with different genotypes. However, HLA-C06 carriers showed poorer response to the applied treatment, when compared to non-carriers. The results of the current study confirm an association between IL12B and IL23R genetic polymorphism and psoriasis vulgaris (with a protective effect of minor alleles). HLA-C*06 carriers show reduced effectiveness of topical/NB-UVB therapy, and that observation could be potentially used in treatment personalization.
白细胞介素-23在银屑病发病机制中起关键作用，在全基因组关联研究中，IL23A、IL12B和IL23R基因变异与该疾病相关。在本文中，我们对来自波兰人群的507例银屑病患者和396例对照进行了病例对照分析，对上述遗传因素进行了验证研究，随后在306例患者的亚组中分析了基因变异对局部和窄谱中波紫外线（NB-UVB）治疗反应的影响。病例对照分析显示，IL12B rs3212227和IL23R rs11209026次要等位基因携带者状态与银屑病患病几率降低相关（OR分别为0.66，95%CI：0.50-0.87和OR为0.41，95%CI：0.26-0.67），而HLA-C06等位基因携带者在患者组中更为常见（OR = 4.56，95%CI：3.41-6.10）。所研究的IL12B、IL23A和IL23R基因多态性变异不影响治疗结果，即不同基因型患者之间的银屑病面积和严重程度指数（PASI）降低无显著差异。然而，与非携带者相比，HLA-C06携带者对所用治疗的反应较差。本研究结果证实了IL12B和IL23R基因多态性与寻常型银屑病之间的关联（次要等位基因具有保护作用）。HLA-C*06携带者的局部/NB-UVB治疗效果降低，这一观察结果可能用于治疗个体化。
